Recent whole-genome and whole-exome deep sequencing of tumor and non-tumor tissues have revealed the importance of somatic mutations and structural variations in tumor development across cancer types and has led to more efficacious treatment modalities based on molecular changes or genomic classification rather than target organs of cancer (e.g., BRAF V600E, KIT, EGFR, ERBB2) (Swanton et al., 2016). This evidence concerns the gene EGFR and cancer.